.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
Cantor Fitzgerald
Farmers Insurance
Healthtrust
Mallinckrodt
Daiichi Sankyo
Express Scripts
Harvard Business School
Dow

Generated: December 14, 2017

DrugPatentWatch Database Preview

VARITHENA Drug Profile

« Back to Dashboard

Which patents cover Varithena, and when can generic versions of Varithena launch?

Varithena is a drug marketed by Provensis and is included in one NDA. There are fifteen patents protecting this drug.

This drug has one hundred and ninety-four patent family members in forty countries.

The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this compound. Additional details are available on the polidocanol profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ProvensisVARITHENApolidocanolSOLUTION;INTRAVENOUS205098-001Nov 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VARITHENA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,048,439Therapeutic foam► Subscribe
9,545,378Aerosol valve► Subscribe
8,091,801Generation of therapeutic microfoam► Subscribe
5,676,962 Injectable microfoam containing a sclerosing agent► Subscribe
7,763,269Therapeutic foam► Subscribe
RE38919 Injectable microfoam containing a sclerosing agent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VARITHENA

Country Document Number Estimated Expiration
Cyprus1110513► Subscribe
China1960705► Subscribe
Bulgaria106248► Subscribe
China1882312► Subscribe
South Korea20060130075► Subscribe
Germany69418286► Subscribe
China1878706► Subscribe
Turkey200103584► Subscribe
Taiwan482671► Subscribe
Denmark0656203► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Army
Novartis
Boehringer Ingelheim
Merck
Farmers Insurance
Federal Trade Commission
AstraZeneca
Covington
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot